Literature DB >> 12949297

Nerve agent attacks on children: diagnosis and management.

Joshua S Rotenberg1, Jonathan Newmark.   

Abstract

Nerve agents (NAs) are the most lethal chemical weapons. We review the pathophysiology and management of NA poisoning of children. NAs cause cholinergic crisis. Children may manifest signs of cholinergic poisoning differently than adults. Children may be less likely to manifest miosis and glandular secretions. They may present with neurologic derangements alone. The goals of treatment should be to limit additional exposure, to provide respiratory support, and to prevent neurologic morbidity. Autoinjectors are optimal delivery vehicles for intramuscular antidotes and are likely to be used in civilian prehospital care. Antidotes include anticholinergics, oximes, and benzodiazepines. Several medications may be available within each class of antidotes. Clinicians will select an antidote based on the status of the individual victim, the accessibility of supportive care, and the availability of the drug. Atropine is well-tolerated and high doses may be required. The oxime pralidoxime chloride has a longer half-life in children. Currently, diazepam is the standard NA anticonvulsant. Midazolam may be the most effective intramuscular anticonvulsant after NA exposure, but, despite its efficacy, it is not an approved agent for seizures. Supportive care and long-term complications are summarized.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12949297     DOI: 10.1542/peds.112.3.648

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  12 in total

Review 1.  Correlating neurobehavioral performance with biomarkers of organophosphorous pesticide exposure.

Authors:  Diane S Rohlman; W Kent Anger; Pamela J Lein
Journal:  Neurotoxicology       Date:  2010-12-21       Impact factor: 4.294

Review 2.  Hospital planning for acts of terrorism and other public health emergencies involving children.

Authors:  S Chung; M Shannon
Journal:  Arch Dis Child       Date:  2005-12       Impact factor: 3.791

3.  Evaluation of first-line anticonvulsants to treat nerve agent-induced seizures and prevent neuropathology in adult and pediatric rats.

Authors:  Liana Matson; Emily Dunn; Kari Haines; Stephanie Miller-Smith; Robyn Lee-Stubbs; Kimberly Whitten; Cherish Ardinger; Hilary McCarren; John McDonough
Journal:  Neurotoxicology       Date:  2019-07-27       Impact factor: 4.294

4.  Paraoxon: An Anticholinesterase That Triggers an Excitotoxic Cascade of Oxidative Stress, Adhesion Responses, and Synaptic Compromise.

Authors:  Karen L G Farizatto; Ben A Bahr
Journal:  Eur Sci J       Date:  2017-10

5.  Inhibitor of Endocannabinoid Deactivation Protects Against In Vitro and In Vivo Neurotoxic Effects of Paraoxon.

Authors:  Karen L G Farizatto; Sara A McEwan; Vinogran Naidoo; Spyros P Nikas; Vidyanand G Shukla; Michael F Almeida; Aaron Byrd; Heather Romine; David A Karanian; Alexandros Makriyannis; Ben A Bahr
Journal:  J Mol Neurosci       Date:  2017-08-12       Impact factor: 3.444

Review 6.  Organophosphorus poisoning (acute).

Authors:  Peter G Blain
Journal:  BMJ Clin Evid       Date:  2011-05-17

7.  A rodent model of human organophosphate exposure producing status epilepticus and neuropathology.

Authors:  W Pouliot; S L Bealer; B Roach; F E Dudek
Journal:  Neurotoxicology       Date:  2016-08-12       Impact factor: 4.294

Review 8.  Organophosphorus poisoning (acute).

Authors: 
Journal:  BMJ Clin Evid       Date:  2007-03-01

9.  Nerve Agent Toxicity and Treatment.

Authors:  Christopher P Holstege; Stephen G Dobmeier
Journal:  Curr Treat Options Neurol       Date:  2005-03       Impact factor: 3.972

10.  Age-dependent behaviors, seizure severity and neuronal damage in response to nerve agents or the organophosphate DFP in immature and adult rats.

Authors:  Erika A Scholl; Stephanie M Miller-Smith; Steven L Bealer; Mark J Lehmkuhle; Jeffrey J Ekstrand; F Edward Dudek; John H McDonough
Journal:  Neurotoxicology       Date:  2018-03-03       Impact factor: 4.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.